| A Study to Assess Concentration of TREMFYA in Breast Milk of Lactating Women Who Are Receiving TREMFYA Therapeutically (NCT07654751) | Janssen Research & Development, LLC | 2026-10-01 |
| A Study of JNJ-95597528 in Participants With Inadequately Controlled Moderate to Severe Asthma (NCT07746687) | Janssen Research & Development, LLC | 2026-09-23 |
| A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC (NCT07586202) | Janssen Research & Development, LLC | 2026-07-28 |
| A Study of Esketamine Nasal Spray Versus Placebo Spray in Adult Participants With Treatment-resistant Depression (NCT07716098) | Janssen Research & Development, LLC | 2026-07-27 |
| A Study to Assess Nipocalimab Concentrations in Breast Milk of Healthy Lactating Women (NCT07669077) | Janssen Research & Development, LLC | 2026-06-23 |
| A Study to Assess Real-World Use and Outcomes of TAR-200 for Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) in the United States (NCT07309445) | Janssen Research & Development, LLC | 2026-06-12 |
| A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma (NCT07518186) | Janssen Research & Development, LLC | 2026-05-31 |
| A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis (NCT07577856) | Janssen Research & Development, LLC | 2026-05-23 |
| A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease (NCT07577843) | Janssen Research & Development, LLC | 2026-05-22 |
| A Study of Persistence to Guselkumab Treatment in Participants With Moderate-to-Severe Plaque Psoriasis in Romania (NCT07582783) | Janssen Research & Development, LLC | 2026-05-15 |
| A Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies (NCT07572006) | Janssen Research & Development, LLC | 2026-05-13 |
| A Real-World Study of Guselkumab in Ulcerative Colitis and Crohn's Disease in Saudi Arabia (NCT07541261) | Janssen Research & Development, LLC | 2026-05-12 |
| A Study of Seltorexant as Monotherapy in Adults and Elderly Participants With Major Depressive Disorder (NCT07573176) | Janssen Research & Development, LLC | 2026-04-30 |
| A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease (NCT07499232) | Janssen Research & Development, LLC | 2026-04-21 |
| A Study of HLD-0117 in Patients With Metastatic Breast Cancer (NCT07524855) | Janssen Research & Development, LLC | 2026-04-09 |
| A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus (NCT07438496) | Janssen Research & Development, LLC | 2026-03-05 |
| A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer (NCT07227025) | Janssen Research & Development, LLC | 2026-03-03 |
| A Study of the Feasibility, Safety and Tolerability of Aticaprant as Adjunctive Treatment in Participants With Schizophrenia (NCT07615426) | Janssen Research & Development, LLC | 2026-03-02 |
| A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma (NCT07266441) | Janssen Research & Development, LLC | 2026-02-08 |
| A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma (NCT07258511) | Janssen Research & Development, LLC | 2026-02-04 |
| A Study of JNJ-95566692 in Participants With Non-Hodgkin Lymphoid Malignancies (NCT07308132) | Janssen Research & Development, LLC | 2026-01-20 |
| A Study of JNJ-95597528 in Participants With Moderate to Severe Atopic Dermatitis (NCT07230860) | Janssen Research & Development, LLC | 2026-01-20 |
| A Study of Nipocalimab in Adult Participants With Active Lupus Nephritis (NCT04883619) | Janssen Research & Development, LLC | 2026-01-15 |
| A Study to Evaluate the Efficacy and Safety of JNJ-88545223 for the Treatment of Participants With Active Psoriatic Arthritis (NCT07321873) | Janssen Research & Development, LLC | 2026-01-15 |
| A Study of Pasritamig (JNJ-78278343) in Combination With JNJ-86974680 for Treatment of Prostate Cancer (NCT07319871) | Janssen Research & Development, LLC | 2026-01-14 |
| A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder (NCT07227454) | Janssen Research & Development, LLC | 2026-01-08 |
| Comparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized Myasthenia Gravis (NCT07217587) | Janssen Research & Development, LLC | 2026-01-05 |
| A Study of JNJ-75276617 in Combination With Conventional Chemotherapy for Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias (NCT05521087) | Janssen Research & Development, LLC | 2025-12-26 |
| A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer (NCT07225946) | Janssen Research & Development, LLC | 2025-12-19 |
| A Study on Hemolytic Disease of the Fetus and Newborn (HDFN) Through Global Registry (NCT07194070) | Janssen Research & Development, LLC | 2025-12-17 |
| A Study of Guselkumab in Participants With Psoriatic Arthritis (PsA) in a Real-World Setting (NCT07220824) | Janssen Research & Development, LLC | 2025-12-04 |
| A Study of Clinical Outcomes in Participants With EGFR Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) in a Real-World Setting (NCT07230691) | Janssen Research & Development, LLC | 2025-12-03 |
| A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer (NCT07276399) | Janssen Research & Development, LLC | 2025-12-03 |
| A Study to Evaluate Sleep Electroencephalogram (EEG) Features (Brain Activity While Sleeping) in Participants With Major Depressive Disorder (MDD) (NCT07258485) | Janssen Research & Development, LLC | 2025-11-24 |
| A Study of 14C-Bleximenib (Radiolabeled) in Participants With Acute Leukemia (NCT07295951) | Janssen Research & Development, LLC | 2025-11-18 |
| A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease (NCT07196722) | Janssen Research & Development, LLC | 2025-10-03 |
| A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel (NCT07149857) | Janssen Research & Development, LLC | 2025-10-03 |
| A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis (NCT07196748) | Janssen Research & Development, LLC | 2025-10-01 |
| A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer (NCT06919965) | Janssen Research & Development, LLC | 2025-09-10 |
| A Study of Pasritamig Versus Placebo in Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC) (NCT07164443) | Janssen Research & Development, LLC | 2025-09-02 |
| A Study of JNJ-95437446 in Participants With Advanced-Stage Solid Tumors (NCT07107230) | Janssen Research & Development, LLC | 2025-07-15 |
| A Study of JNJ-78278343 in Combination With JNJ-95298177 for Treatment of Prostate Cancer (NCT07082920) | Janssen Research & Development, LLC | 2025-07-07 |
| A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) (NCT06852222) | Janssen Research & Development, LLC | 2025-06-04 |
| A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis (NCT06934226) | Janssen Research & Development, LLC | 2025-04-15 |
| A Study of JNJ-90189892 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms (NCT06651229) | Janssen Research & Development, LLC | 2025-03-21 |
| A Study of JNJ-95475939 in the Treatment of Participants With Moderate to Severe Atopic Dermatitis (AD) (NCT06881251) | Janssen Research & Development, LLC | 2025-02-26 |
| A Study to Evaluate the Efficacy and Safety of JNJ-77242113 (Icotrokinra) in Biologic-naïve Participants With Active Psoriatic Arthritis (NCT06878404) | Janssen Research & Development, LLC | 2025-02-21 |
| Study of HLD-0915 in Patients With Metastatic Prostate Cancer (NCT06800313) | Janssen Research & Development, LLC | 2025-02-20 |
| A Study of Nipocalimab or Intravenous Immunoglobulin (IVIG) in Pregnancies At Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT) (NCT06533098) | Janssen Research & Development, LLC | 2025-02-10 |
| A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced and Biologic-naive Participants With Active Psoriatic Arthritis (NCT06807424) | Janssen Research & Development, LLC | 2025-01-09 |
| A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring (NCT06788509) | Janssen Research & Development, LLC | 2024-12-30 |
| A Study to Explore the Efficacy of JNJ-89495120 in the Treatment of Major Depressive Disorder (NCT06785012) | Janssen Research & Development, LLC | 2024-12-26 |
| A Study of JNJ-87562761 in Participants With Relapsed or Refractory Multiple Myeloma (NCT06604715) | Janssen Research & Development, LLC | 2024-12-19 |
| A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) (NCT06667076) | Janssen Research & Development, LLC | 2024-12-16 |
| A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy (NCT06750094) | Janssen Research & Development, LLC | 2024-12-12 |
| Nipocalimab in Moderate to Severe Sjogren's Disease (NCT06741969) | Janssen Research & Development, LLC | 2024-12-04 |
| A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide or in Combination With Pomalidomide for Multiple Myeloma (NCT06768489) | Janssen Research & Development, LLC | 2024-12-04 |
| A Study of Nipocalimab in Reducing the Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT) (NCT06449651) | Janssen Research & Development, LLC | 2024-11-11 |
| A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants (NCT06663332) | Janssen Research & Development, LLC | 2024-10-29 |
| A Study of JNJ-80948543 in Combination With Other CD3 T-Cell Engagers in Participants With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (R/R B-Cell NHL) (NCT06660563) | Janssen Research & Development, LLC | 2024-10-22 |
| A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer (NCT06662786) | Janssen Research & Development, LLC | 2024-10-18 |
| A Study of JNJ-89402638 for Metastatic Colorectal and Gastric Cancers (NCT06663319) | Janssen Research & Development, LLC | 2024-10-15 |
| A Follow-on Study for Second-Eye Treatment for Participants Previously Treated With Gene Therapy for X-Linked Retinitis Pigmentosa (XLRP) (NCT06646289) | Janssen Research & Development, LLC | 2024-10-10 |
| A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) (NCT06635148) | Janssen Research & Development, LLC | 2024-09-19 |
| A Study of Aticaprant Plus an Antidepressant to Prevent Return of Depression Symptoms in Participants With Major Depressive Disorder Who Experience a Loss of Interest and Pleasure (NCT06635135) | Janssen Research & Development, LLC | 2024-09-19 |
| A Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple Myeloma (NCT06550895) | Janssen Research & Development, LLC | 2024-09-16 |
| A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events (NCT06500884) | Janssen Research & Development, LLC | 2024-08-26 |
| A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma (NCT06577025) | Janssen Research & Development, LLC | 2024-08-20 |
| Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms (NCT06559306) | Janssen Research & Development, LLC | 2024-07-25 |
| A Study of Combination Therapy With Amivantamab and Docetaxel in Participants With Metastatic Non-small Cell Lung Cancer (NCT06532032) | Janssen Research & Development, LLC | 2024-07-23 |
| A Study of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy and Long-term Extension Treatment With Aticaprant (NCT06514742) | Janssen Research & Development, LLC | 2024-06-26 |
| A Study Comparing Pre- and Post-Change Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma (NCT06425991) | Janssen Research & Development, LLC | 2024-06-07 |
| A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia (NCT05963074) | Janssen Research & Development, LLC | 2024-05-30 |
| A Study of JNJ-88998377 for Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma (NCT06470438) | Janssen Research & Development, LLC | 2024-05-28 |
| A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer (NCT06385080) | Janssen Research & Development, LLC | 2024-04-22 |
| A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer (NCT06319820) | Janssen Research & Development, LLC | 2024-04-18 |
| A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG) (NCT06211764) | Janssen Research & Development, LLC | 2024-04-09 |
| A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease (NCT05923073) | Janssen Research & Development, LLC | 2024-03-13 |
| A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2) (NCT06220604) | Janssen Research & Development, LLC | 2024-03-09 |
| A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (NCT06143878) | Janssen Research & Development, LLC | 2024-02-01 |
| A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide (NCT06208150) | Janssen Research & Development, LLC | 2024-01-22 |
| A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis (NCT06260163) | Janssen Research & Development, LLC | 2024-01-19 |
| A Study of Sterile Saline Infusion in Healthy Volunteers (NCT06194578) | Janssen Research & Development, LLC | 2024-01-12 |
| A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms (NCT06150157) | Janssen Research & Development, LLC | 2023-12-20 |
| A Study of Nipocalimab in Pregnancies at Risk for Severe Hemolytic Disease of the Fetus and Newborn (HDFN) (NCT05912517) | Janssen Research & Development, LLC | 2023-12-20 |
| A Study of JNJ-87890387 for Advanced Solid Tumors (NCT06178614) | Janssen Research & Development, LLC | 2023-12-14 |
| A Study of JNJ-87801493 in Combination With T-Cell Engagers in Participants With B-cell Non-Hodgkin Lymphoid (NHLs) Cancer (NCT06139406) | Janssen Research & Development, LLC | 2023-12-06 |
| Study to Evaluate the Safety and Efficacy of PIPE-307 in Subjects With Relapsing-Remitting Multiple Sclerosis (NCT06083753) | Janssen Research & Development, LLC | 2023-11-06 |
| A Study of JNJ-90009530 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (r/r B-NHL) (NCT05784441) | Janssen Research & Development, LLC | 2023-11-06 |
| A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer (NCT06095089) | Janssen Research & Development, LLC | 2023-11-01 |
| A Study of 9-valent Extraintestinal Pathogenic Escherichia Coli Vaccine (ExPEC9V) and High-dose Quadrivalent Influenza Vaccine, With and Without Co-administration, in Adults Aged 65 Years or Older (NCT06134804) | Janssen Research & Development, LLC | 2023-10-24 |
| A Study of JNJ-77242113 for the Treatment of Participants With Plaque Psoriasis Involving Special Areas (Scalp, Genital, and/or Palms of the Hands and the Soles of the Feet) (NCT06095102) | Janssen Research & Development, LLC | 2023-10-12 |
| A Study of JNJ-77242113 in Participants With Moderately to Severely Active Ulcerative Colitis (NCT06049017) | Janssen Research & Development, LLC | 2023-10-09 |
| Global Patient Registry of Inherited Retinal Diseases (NCT05957276) | Janssen Research & Development, LLC | 2023-08-31 |
| A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC (NCT05884398) | Janssen Research & Development, LLC | 2023-08-31 |
| Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (NCT06039189) | Janssen Research & Development, LLC | 2023-08-24 |
| A Study to Evaluate the Nipocalimab and Certolizumab Combination Therapy in Participants With Active Rheumatoid Arthritis (NCT06028438) | Janssen Research & Development, LLC | 2023-08-15 |
| A Study of Lazertinib (JNJ-73841937) Tablet in Healthy Adult Participants (NCT05896683) | Janssen Research & Development, LLC | 2023-05-30 |
| A Study of Adalimumab on Inflammatory Mediators Following a Systemic Endotoxin Challenge (NCT05884242) | Janssen Research & Development, LLC | 2023-05-22 |
| A Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell Lung Cancer (NCT05908734) | Janssen Research & Development, LLC | 2023-05-18 |